Focused On-demand Library for ADP-ribosylation factor-like protein 6-interacting protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q15041

UPID:

AR6P1_HUMAN

Alternative names:

Apoptotic regulator in the membrane of the endoplasmic reticulum

Alternative UPACC:

Q15041; B7Z6S5; B7Z791; F5GXP4

Background:

ADP-ribosylation factor-like protein 6-interacting protein 1, alternatively known as Apoptotic regulator in the membrane of the endoplasmic reticulum, plays a pivotal role in various cellular processes. It enhances SLC1A1/EAAC1-mediated glutamate transport, contributes to endoplasmic reticulum tubule stability, and modulates apoptosis by influencing caspase-9 activity. Its involvement in protein transport, membrane trafficking, and cell signaling during hematopoietic maturation underscores its multifunctionality.

Therapeutic significance:

Linked to Spastic paraplegia 61, autosomal recessive, a neurodegenerative disorder, ADP-ribosylation factor-like protein 6-interacting protein 1's study could lead to novel therapeutic interventions. Understanding its role in glutamate transport and apoptosis regulation offers insights into potential strategies for managing this and related neurological conditions.